Previous 10 | Next 10 |
The shares of Athenex Inc. ( NASDAQ: ATNX ) climbed ~70% on rising volumes in the post-market Thursday in reaction to reports that India’s Dr Reddy's Laboratories ( RDY ) and Intas Pharmaceuticals are in talks to acquire the cancer-focused biotech. The compa...
Athenex, Inc. (ATNX) Q2 2022 Earnings Conference Call July 28, 2022 08:00 ET Company Participants Caileigh Dougherty - Director, Investor Relations Johnson Lau - Chief Executive Officer Dan Lang - President, Athenex Cell Therapy Darrel Cohen - Chief Medical O...
Athenex press release ( NASDAQ: ATNX ): Q2 GAAP EPS of -$0.28 misses by $0.13 . Revenue of $25.79M (+17.7% Y/Y) misses by $5.47M . Shares +5% PM. Athenex continues to expect product sales from continuing operations growth to be in the range of 20-25% ov...
Reports 2Q product sales of $25.8 million, up 26% year-over-year Raised $85 million in total transaction value in 2Q for total of $125 million in proceeds from sales of non-core assets in 1H 2022, and reduced Senior Credit Facility balance from $150 million to $57.5 million ...
Athenex ( NASDAQ: ATNX ) is scheduled to announce Q2 earnings results on Thursday, July 28th, before market open. The consensus EPS Estimate is -$0.20 (+39.4% Y/Y) and the consensus Revenue Estimate is $31.26M (+42.6% Y/Y). Over the last 1 year, ATNX has beaten EPS e...
BUFFALO, N.Y., July 25, 2022 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced the publication of their m...
BUFFALO, N.Y., July 21, 2022 (GLOBE NEWSWIRE) -- Athenex (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that the Company will provide...
Athenex ( NASDAQ: ATNX ) and certain affiliates to sell all of its equity interests in its China subsidiaries, which are primarily engaged in Active Pharmaceutical Ingredient (API) manufacturing operations, to TiHe Capital Co., Ltd. for RMB 124.4 million, or ~$19M. Athenex wil...
Expected sale proceeds of approximately $19.0 million Company continues to monetize non-core assets to extend cash runway Proceeds from the deal will be used to pay down debt and fund operations BUFFALO, N.Y., July 11, 2022 (GLOBE NEWSWIRE) -- Athenex, In...
BUFFALO, N.Y., June 23, 2022 (GLOBE NEWSWIRE) -- Athenex (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that Daniel Lang, M.D., Presi...
News, Short Squeeze, Breakout and More Instantly...
Athenex Inc. Company Name:
ATNX Stock Symbol:
NASDAQ Market:
To Best Facilitate, Company Voluntarily Files Chapter 11 Proceedings Company Has Sufficient Resources to Support Athenex Pharma Solutions Operations and Fulfill APD Customer Orders During Process BUFFALO, N.Y., May 14, 2023 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX) (...
Quantum Leap Healthcare Collaborative Announces Result of Oral Paclitaxel in Combination with a PD-1 and Carboplatin from I-SPY2 TRIAL at ASCO PR Newswire SAN FRANCISCO , May 1, 2023 /PRNewswire/ -- Quantum Leap Healthcare Collaborative (Quantum Leap) and At...
Exploring a range of strategic alternatives Revenues from product sales from continued operations increased +27% Y/Y in 4Q 2022 and +33% for full year 2022 Net Loss attributable to Athenex was $34.2 million, or $4.28 per diluted share in 4Q2022, compared to $104.4 million, or $1...